Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer (ARGO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02664077
Recruitment Status : Terminated (Due to the significantly lower than expected accrual it was impossible to evaluate the endpoint in a timely fashion.)
First Posted : January 26, 2016
Last Update Posted : September 10, 2020
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
NSABP Foundation Inc

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : October 2019
Actual Study Completion Date : October 2019